当基因组检测结果与标准检测结果出现差异时：对乳腺癌患者化疗偏好的影响
When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.
作者信息
Brewer Noel T, Edwards Alrick S, O'Neill Suzanne C, Tzeng Janice P, Carey Lisa A, Rimer Barbara K
机构信息
Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, 27516, USA.
出版信息
Breast Cancer Res Treat. 2009 Sep;117(1):25-9. doi: 10.1007/s10549-008-0175-2. Epub 2008 Sep 11.
PURPOSE
We examined how women incorporate potentially differing genomic and standard assessments of breast cancer recurrence risk into chemotherapy decisions.
METHODS
165 women previously treated for early-stage breast cancer indicated their interest in chemotherapy regimens to prevent recurrence of breast cancer in response to six hypothetical vignettes that presented breast cancer recurrence risk estimates from standard criteria and a genomic test, some of which were discordant.
RESULTS
Standard and genomic test results each elicited greater interest in chemotherapy when they indicated high rather than low risk for recurrence (89% vs. 26%, and 87% vs. 22%, respectively, Ps < 0.001). Genomic test results had a larger impact on chemotherapy preferences than standard measures to predict recurrence.
CONCLUSIONS
Some women may be reluctant to forgo chemotherapy when genomic tests indicate low recurrence risk but standard criteria suggest high risk. Additional research including replication of the findings of this small, vignette-based study is needed.
目的
我们研究了女性如何将潜在不同的乳腺癌复发风险的基因组评估和标准评估纳入化疗决策。
方法
165名曾接受早期乳腺癌治疗的女性，针对六个假设的病例 vignette 表明了她们对预防乳腺癌复发的化疗方案的兴趣，这些病例呈现了来自标准标准和基因组检测的乳腺癌复发风险估计，其中一些是不一致的。
结果
当标准和基因组检测结果表明复发风险高而非低时，每种结果都引发了对化疗更大的兴趣（分别为89%对26%，87%对22%，P<0.001）。基因组检测结果对化疗偏好的影响比预测复发的标准措施更大。
结论
当基因组检测表明复发风险低但标准标准提示高风险时，一些女性可能不愿意放弃化疗。需要进行更多研究，包括重复这项基于病例 vignette 的小型研究的结果。
Zotero 插件